β galactosidase enzyme fragment complementation as a high-throughput screening protease technology

被引:31
作者
Naqvi, T [1 ]
Lim, A [1 ]
Rouhani, R [1 ]
Singh, R [1 ]
Eglen, RM [1 ]
机构
[1] DiscoveRx Corp, Fremont, CA 94538 USA
关键词
enzyme fragment complementation; beta galactosidase; protease assays; caspase; 3; beta secretase; BACE;
D O I
10.1177/1087057104264040
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The authors describe a homogeneous, high-throughput screening (FITS) assay for measuring protease activity and detection of inhibitors. The assay comprises a cyclic beta-galactosidase (beta-gal) enzyme donor peptide (ED) containing a protease-selective cleavage sequence. Alone, the cyclic peptide is inactive, but when linearized following protease cleavage, ED complements with beta-gal enzyme acceptor forming active beta-gal enzyme. This then catalyzes the formation of either fluorescent or chemiluminescent products, with beta-gal turnover providing a highly amplified signal, and thus an assay technology of high sensitivity. To demonstrate the utility of the technology, an EFC assay was developed to measure the activity of 2, caspase 3 and beta-secretase. Using a cyclic ED containing the caspase 3 substrate sequence, DEVD, the EFC assay signal was linear with respect to caspase 3 concentration. The assay was very sensitive, being able to detect activity at low picogram amounts of caspase 3. For the beta-secretase (BACE) EFC assay, a cyclic ED containing the Swedish mutant cleavage site of amyloid precursor protein (APP), SEVNLDAEFK, was used. In a similar fashion to the caspase 3 assay, the signal induced by BACE activity was linear with respect to enzyme concentration and was highly sensitive, being able to detect nanogram quantities of BACE. The assay was also more sensitive than a commercially available FRET-based assay of BACE activity. It is concluded that the EFC protease assay is a simple, flexible, and sensitive technology for HTS of proteases.
引用
收藏
页码:398 / 408
页数:11
相关论文
共 29 条
[1]   Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity [J].
Andersen, H ;
Greenberg, DL ;
Fujikawa, K ;
Xu, WF ;
Chung, DW ;
Davie, EW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (20) :11189-11193
[2]  
BLAKE J, 1975, INT J PEPT PROT RES, V7, P495
[3]  
Chan WC, 2000, FMOC SOLID PHASE PEP, P277
[4]   Enzyme fragment complementation: A flexible high throughput screening assay technology [J].
Eglen, RM .
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 2002, 1 (01) :97-104
[5]  
Eglen RM, 2003, COMB CHEM HIGH T SCR, V6, P381
[6]   Conformational selection of inhibitors and substrates by proteolytic enzymes: Implications for drug design and polypeptide processing [J].
Fairlie, DP ;
Tyndall, JDA ;
Reid, RC ;
Wong, AK ;
Abbenante, G ;
Scanlon, MJ ;
March, DR ;
Bergman, DA ;
Chai, CLL ;
Burkett, BA .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (07) :1271-1281
[7]   Evaluation of an imaging platform during the development of a FRET protease assay [J].
George, J ;
Teear, ML ;
Norey, CG ;
Burns, DD .
JOURNAL OF BIOMOLECULAR SCREENING, 2003, 8 (01) :72-80
[8]   A homogeneous enzyme fragment complementation cyclic AMP screen for GPCR agonists [J].
Golla, R ;
Seethala, R .
JOURNAL OF BIOMOLECULAR SCREENING, 2002, 7 (06) :515-525
[9]   Substrate and inhibitor profile of BACE (β-secretase) and comparison with other mammalian aspartic proteases [J].
Grüninger-Leitch, F ;
Schlatter, D ;
Küng, E ;
Nelböck, P ;
Döbeli, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (07) :4687-4693
[10]   Identification of β-secretase-like activity using a mass spectrometry-based assay system [J].
Grüninger-Leitch, F ;
Berndt, P ;
Langen, H ;
Nelboeck, P ;
Döbeli, H .
NATURE BIOTECHNOLOGY, 2000, 18 (01) :66-70